These cognitive tests are often supplemented by neuroimaging and biomarker analysis for a more precise diagnosis, such as Magnetic resonance imaging (MRI) to assess brain atrophy, PET scan to assess the levels of Aβ and tau, and CSF analysis to assess the levels of several biomarkers [52]. The gene discussed is MAPT; the disease is Brain atrophy.